Definition

A preparation of autologous T lymphocytes that have been genetically modified and transduced with a gamma-retrovirus vector expressing a second-generation chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 DASH CAR-T cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.